

## DAFTAR PUSTAKA

- Abell, K. & Watson, C. J. 2005. The jak/stat pathway: a novel way to regulate PI3K activity. *Cell Cycle*. 4(7): 897-900.
- Bange, J., Zwick, E., & Ullrich, A. 2001. Molecular targets for breast cancer therapy and prevention. *Nat Med*, 7(5): 548-52.
- Barone, I., Brusco, L., & Fuqua, S. A. W. 2010. Estrogen receptor mutations and changes in downstream gene expression and signaling, *118*(12): 2702-2709.
- Beckmann, M. W., Niederacher, D., Schnurch, H-G., Gusterson, B. A., Bender, H-G. 1997. Multistep carcinogenesis of breast cancer tumour heterogeneity. *J Mol Med*. 75: 429-39.
- Berishaj, M., Gao, S. P., Ahmed, S., Leslie, K., Al-ahmadie, H., Gerald, W. L., Bromberg, J. F. 2007. Stat3 is tyrosine-phosphorylated through the interleukin-6 / glycoprotein 130 / Janus kinase pathway in breast cancer. *Breast Cancer Res*, 9(3): 1-8.
- Bhat-nakshatri, P., Wang, G., Collins, N. R., Thomson, M. J., Geistlinger, T. R., Carroll, J. S., Nakshatri, H. 2009. Estradiol-regulated microRNAs control estradiol response in breast cancer cells, *37*(14): 4850-4861.
- Bischoff, A., Bayerlova, M., Strotbek, M., Schmid, S., Beissbarth, T., & Olayioye, M. O. 2015. A global microRNA screen identifies regulators of the ErbB receptor signaling network. *Cell Comm Sig*. 13 (5): 1-15.
- Blenkiron, C., Goldstein, L. D., Thorne, N. P., Spiteri, I., Chin, S.-F., Dunning, M. J., Miska, E. a. 2007. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. *Genome Biol*, 8(10): R214.1-16.
- Brase, J. C., Wuttig, D., Kuner, R., & Sultmann, H. 2010. Serum microRNAs as non-invasive biomarkers for cancer. *Mol Cancer*, 9(1): 1-9.
- Chan, H. S., & Zhang, Z. 2009. Liaison amid disorder: non-native interactions may underpin long-range coupling in proteins. *Journal of Biology*, 8(3): 27.
- Chang, S., & Sharan, S. K. 2012. BRCA1 and microRNAs: emerging networks and potential therapeutic targets. *Mol. Cells*, 34(5): 425-32.
- Chang, S., Wang, R.H., Akagi, K., Kim, K.A., Martin, B.K., Cavallone, L., Haines, D.C., Basik, M., Mai, P., Poggi, E., et al. 2011. Tumor suppressor

BRCA1 epigenetically controls oncogenic microRNA-155. *Nat. Med.* 17: 1275-82.

Chen, X., Liang, H., Zhang, J., Zen, K., & Zhang, C.-Y. 2012. Secreted microRNAs: a new form of intercellular communication. *Trends in Cell Biology*, 22(3): 125–32.

Cheng, G. 2015. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. *Advanced Drug Delivery Reviews*, 81: 75–93.

Cho, W. C.S (Eds). 2011. *MicroRNAs in Cancer Translational Research*. Springer, New York.

Chu, Y., Yue, X., Younger, S.T., Janowski, B.A. & Corey, D.R. (2010). Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. *Nucl. Acid Res.* 38 (21): 7736-48

Cirillo, D., Rachiglio, A.M, la Montagna, R., Giordano, A., Normanno, N. 2008. Leptin signaling in breast cancer: an overview. *J Cell Biochem.* 105:956–64  
Croche, C. M. 2008. Molecular origins of cancer: oncogenes and cancer. *N Engl J Med.* 358 : 502-11

Cochrane, D. R., Cittelty, D. M., & Richer, J. K. 2011. Steroid receptors and microRNAs: relationships revealed. *Steroids*, 76(1-2): 1–10.

Cochrane, D. R., Spoelstra, N. S., & Richer, J. K. 2012. The role of miRNAs in progesterone action. *Molecular and Cellular Endocrinology*, 357(1-2): 50–9.

Corcoran, C., Friel, A. M., Duffy, M. J., Crown, J., & O’Driscoll, L. 2011. Intracellular and extracellular microRNAs in breast cancer. *Clin Chem*, 57(1): 18–32.

Cortez, M. A., Bueso-ramos, C., Ferdin, J., Lopez-berestein, G., Sood, A. K., & Calin, G. A. 2011. MicroRNAs in body fluids—the mix of hormones and biomarkers. *Nat Rev Clin Oncol*, 8(8): 467–77.

Croker, B. A., Kiu, H., & Nicholson, S. E. 2009. SOCS regulation of the JAK/STAT signaling pathway. *Semin Cell Dev Biol*, 19(4): 414–22.

Davoren, P.A, McNeill, R.E., Lowery, A.J., Kerin, M.J., Miller, N. 2008. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. *BMC Mol Biol.* 9:76-87.

- Davis, N.M., Sokolosky, M., Stadelman, M., Adams, S.L., Libra, M., Candido, S. McCubrey, J.A. 2014. Deregulation of EGFR/PI3K/PTEN/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. *Oncotarget*. 5(13):4603-50.
- Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K., & Schwarzenbach, H. 2013. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. *Clin Chem*. 59(10): 1489–96.
- Fang, B. 2014. Genetic interactions of STAT3 and anticancer drug development. *Cancers*, 6(1): 494–525.
- Faraoni, I., Antonetti, F. R., Cardone, J., & Bonmassar, E. 2009. MiR-155 gene: a typical multifunctional microRNA. *Biochim Biophys Acta*. 1792(6): 497–505.
- Fu, S., Chen, L., & Man, Y. 2011. miRNA biomarkers in breast cancer and detection and management. *J. Cancer*. 2 : 116-22.
- Garzon, R., Calin, G. a, & Croce, C. M. 2009. MicroRNAs in cancer. *Annu Rev Med*, 60: 167–79.
- Garzon, R., Marcucci, G., & Croce, C. M. 2010. Targeting microRNAs in cancer: rationale, strategies and challenges. *Nat Rev Drug Discov*, 9(10): 775–789.
- Gasparini, P., Cascione, L., Fassan, M., & Lovat, F. 2014. MicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. *Oncotarget*, 5(5): 1174–84.
- Gupta, N., Grebhardt, S., & Mayer, D. 2012. Janus kinase 2--a novel negative regulator of estrogen receptor  $\alpha$  function. *Cellular Signalling*. 24(1): 151–61.
- Gupta, N., & Mayer, D. 2013. Interaction of JAK with steroid receptor function Interaction of JAK with steroid receptor function. *JAK-STAT*. 2: 37–41.
- Gurses, H. E., Hatipoğlu O. F., & Gunduz, M. 2015. *MicroRNAs as Therapeutic Targets in Human Breast Cancer, A Concise Review of Molecular Pathology of Breast Cancer*. Prof. Mehmet Gunduz (Ed.), ISBN: 978-953-51-2030-8, InTech, DOI: 10.5772/59681. Available from: <http://www.intechopen.com/books/a-concise-review-of-molecular-pathology-of-breast-cancer/micrnas-as-therapeutic-targets-in-human-breast-cancer>

Hans, F. P., Moser, M., Bode, C., & Grundmann, S. 2010. MicroRNA regulation of angiogenesis and arteriogenesis. *TCM* 20(8): 253–62.

Haryono, S.J. 2012. *Kanker Payudara Familial: Penelusuran Gena dan Predisposisi Terwaris dan Perhitungan Risiko*. Fakultas Kedokteran Universitas Gadjah Mada.

Hayashi, S., Eguchi, H., Tanimoto, K., Yoshida, T., Omoto, Y., & Inoue, A. 2003. The expression and function of estrogen receptor  $\alpha$  and  $\beta$  in human breast cancer and its clinical application, 193–202.

Henry M.D., Triplett A.A., Oh K.B., Smith G.H., Wagner K.U. 2004. Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice. *Oncogene*. 23 (41): 6980–85.

<http://www.cancer.org>.

<http://www.genecard.org>.

<http://www.mirtarbase.org>.

<http://www.ncbi.nlm.nih.gov/nuccore/4507232>

<http://www.who.int>

Huang, C., Li, H., Wu, W., Jiang, T. A. O., & Qiu, Z. 2013. Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1. *Oncol Rep*. 30: 1223–30.

Huang, Y., Yang, Y. B., Zhang, X. H., Yu, X. L., Wang, Z. Bin, & Cheng, X. C. 2013. MicroRNA-21 gene and cancer. *Med Oncol*. 30: 376–85.

Inagaki-ohara, K., Kondo, T., Ito, M., & Yoshimura, A. 2013. SOCS , inflammation , and cancer. *JAK-STAT*. 2(3): 1–10.

Iorio, M. V., & Croce, C. M. 2012. Causes and consequences of microRNA dysregulation. *Cancer J*. 18(3): 215–22.

Iorio, M. V, & Croce, C. M. 2009. MicroRNAs in cancer: small molecules with a huge impact. *J Clin Oncol*. 27(34): 5848–56.

Iorio, M. V, & Croce, C. M. 2012. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Mol Med*. 4(3): 143–59.

- Jacobsen, B. M., & Horwitz, K. B. 2012. Progesterone receptors, their isoforms and progesterone regulated transcription. *Molecular and Cellular Endocrinology*. 357(1-2): 18–29.
- Jiang, S., Zhang, H., & Lu, M. 2010. MicroRNA-155 functions as an oncomiR in breast cancer by targeting the Suppressor of Cytokine Signaling 1 gene. *Cancer Res*. 70: 3119–27.
- Kang, K., Peng, X., Luo, J., & Gou, D. 2012. Identification of circulating miRNA biomarkers based on global quantitative real-time PCR profiling. *J Anim Sci Biotech*. 3: 1–9.
- Kapinas, K. & Delany, A.M. 2011. MicroRNA biogenesis and regulation of bone remodeling. *Arthr Res Ther*. 13: 220.
- Kazi, J., Kabir, N., Flores-Morales, A., Ronnstrand, L. 2014. SOCS protein regulation of receptor tyrosine kinase signaling. *Cell Mol Life Sci*. (Publish online).
- Kim, J. E., Patel, M., Ruzevick, J., Jackson, C. M., & Lim, M. 2014. STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications. *Cancers*. 6(1): 376–95.
- Kong, W., He, L., Coppola, M., Guo, J., Esposito, N. N., Coppola, D., & Cheng, J. Q. 2010. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. *The Journal of Biological Chemistry*. (published online).
- Kosaka, N., Iguchi, H., & Ochiya, T. (2010). Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. *Cancer Sci*. 101(10): 2087–92.
- Krebs, D. L. & Hilton, D.J. 2001. SOCS proteins : negative regulators of cytokine signaling. *Stem cell*. 19: 378-87.
- Kresno, S. B. 2011. Micro-RNA dan implikasinya pada kanker. *Indonesian Journal of Cancer*. 5(3): 119–27.
- Li, M., Marin-Muller, C., Bharadwaj, U., Chow, K.-H., Yao, Q., & Chen, C. 2009. MicroRNAs: control and loss of control in human physiology and disease. *World J Surg*. 33(4): 667–84.
- Liu, J., Mao, Q., Liu, Y., Hao, X., Zhang, S., & Zhang, J. 2013. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. *Chin J Cancer Res*. 25(1): 46–54.

- Liu, L., Li, W., Wei, X., Cui, Q., Lou, W., Wang, G., Qian, C. 2013. Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma. *Gene Ther.* 29: 84–92.
- Lowery, A.J., Miller, N., Devaney, A., McNeill, R.E., Davoren, P. A., Lemetre, C. et al. 2009. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/*neu* receptor status in breast cancer. *Breast Cancer Res.* 11(3):1-18
- Lu, Z., Ye, Y., Jiao, D., Qiao, J., Cui, S., & Liu, Z. 2012. MiR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. *Oncology Letters.* 4(5): 1027–32.
- Maiolot, G., Lacroix-Triki, M., Pierredon, S., Gratadou, L., Schmidt, S., Benes, V., et al., 2009. Widespread estrogen dependent repression of microRNAs involved in breast tumor cell growth. *Cancer Res.* 69 : 8332-40.
- Mallette, A., Calabrese, V., Ilangumaran, S., & Ferbeyre, G. 2010. A novel interaction partner of p53 controlling oncogene - induced senescence. *Aging.* 2(7): 445–52.
- Marini, A., Mirmohammadsadegh, A., Nambiar, S., Gustrau, A., Ruzicka, T., & Hengge, U. R. 2006. Epigenetic Inactivation of Tumor Suppressor Genes in Serum of Patients with Cutaneous Melanoma. *126*: 422–431.
- Mattiske, S., Suetani, R. J., Neilsen, P. M., & Callen, D. F. 2012. The oncogenic role of miR-155 in breast cancer. *Cancer Epidemiol Biomarkers Prev.* 21(8): 1236–43.
- Maynadier, M., Nirdé, P., Ramirez, J., Cathiard, A. M., Chambon, M., Garcia, M. 2008. Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells. *Advanc Experiment Medic Biol.* 617 : 485-91
- McPherson, K., Steel, C.M., Dixon, J.M. 2000. Breast cancer-epidemiology, risk factor, and genetics. *BMJ.* 321:624-8.
- Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-agadjanyan, E. L., Tewari, M. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. *PNAS.* 105(30): 10513–18.
- Murray, P. J. 2007. The JAK-STAT signaling pathway: input and output integration. *J Immunol.* 178: 2623–29.
- Pan, Y. 2013. Role of Stat3 in nasopharyngeal carcinoma. *OA Cancer.* 1(2): 1–5.



- Pritchard, C. C., Cheng, H. H., & Tewari, M. 2012. MicroRNA profiling : approaches and considerations. *Nat Rev.* 13: 358–69.
- Quitas-Cardama, A. & Verstovsek, S. 2013. Molecular pathways : JAK/STAT pathway: mutations, inhibitors and resistance. *Clin Cancer Res.* 19(8): 1933-40.
- Ragan, C., Zuker, M., Ragan, M.A. 2011. Quantitative prediction of miRNA-mRNA interaction based on equilibrium concentrations. *PLoS Compt Biol.* 7 (2): e10001090.
- Raponi, M., Dossey, L., Jatko, T., Wu, X., Chen, G., Fan, H., & Beer, D. G. 2009. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. *Cancer Res.* 69(14): 5776–83.
- Rawlings, J. S., Kristin, M., & Harrison, D. A. 2004. The JAK / STAT signaling pathway. *J Cell Sci.* 1(117): 1281–83.
- Sasi, W., Jiang, W. G., Sharma, A., & Mokbel, K. 2010. Higher expression levels of SOCS 1 , 3 , 4 , 7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. *BMC Cancer.* 10(178): 1–13.
- Sasi, W., Sharma, A. K., Mokbel, K., London, T., Princess, T., Hospital, G., Wu, L. 2014. The role of Suppressors of Cytokine Signalling in human neoplasms. *Mol Biol Int.* : 1–24.
- Sassen, S., Miska, E. a, & Caldas, C. 2008. MicroRNA: implications for cancer. *Virchows Arch.* 452(1): 1–10.
- Schetter, A., Okayama, H., Harris, C. 2013. The role of microRNAs in colorectal cancer. *Cancer J.* 18 : 244-52.
- Schooneveld, E. Van, Wouters, M. C. A., Auwera, I. Van Der, Peeters, D. J., Wildiers, H., Dam, P. A. Van, Laere, S. J. Van. 2012. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with ( metastatic ) breast cancer and healthy volunteers. *Breast Cancer Res.* 14: 1–16.
- Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K. 2014. Clinical relevance of circulating cell-free microRNAs in cancer. *Nat Rev Clin Oncol.* 1–12.
- Shenouda, S. K., & Alahari, S. K. 2009. MicroRNA function in cancer: oncogene or a tumor suppressor? *Cancer Metastasis Rev.* 28: 369–78.

- Shuai, K., & Liu, B. 2003. Regulation of JAK – STAT. *Nat Rev.* 3:900–11.
- Singh, R. & Mo. Y. 2013. Role of microRNAs in breast cancer. *Can Biol Ther.* 14 (3) : 201-212.
- Slack, F.J. & Weidhaas, J.B. 2008. MicroRNA in cancer prognosis. *N Engl J Med.* 25(359): 2720-22.
- Sørli, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Børresen-dale, A. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *PNAS.* 98(19): 10869–74.
- Souma, Y., Nishida, T., Serada, S., Iwahori, K., Takahashi, T., & Fujimoto, M. 2012. Antiproliferative effect of SOCS-1 through suppression STAT3 and p38 MAPK activation in gastric cancer cells. *Int J Cancer.* 1296: 1287–96.
- Suarez, Y., & Sessa, W. C. 2009. MicroRNAs as novel regulators of angiogenesis. *Circ Res.* 104(4): 442–54.
- Sui, X., Wang, X., Han, W., Li, D., Xu, Y., Lou, F., Pan, H. 2015. MicroRNAs-mediated cell fate in triple negative breast cancers. *Cancer Letters.* 361(1): 8–12.
- Sukardja, I.D.G. 2000. *Onkologi Klinik Ed.2.* Airlangga University Press.
- Sun, Y., Wang, M., Lin, G., Sun, S., Li, X., Qi, J., & Li, J. 2012. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. *PloS One.* 7(10): 1–8.
- Tahiri, A. Leivonen S-K., Luders, T., Steinfeld, I. Aure, M.R., & Geisler, J. 2013. deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumor. *Carcinogenesis.* published online.
- Tang, J., Ahmad, A., & Sarkar, F. H. 2012. The role of microRNAs in breast cancer migration, invasion and metastasis. *Int J Mol Sci.* 13(10): 13414–37.
- Tanos, T., Rojo, L. J., Echeverria, P., & Briskin, C. 2012. ER and PR signaling nodes during mammary gland development. *Breast Can Res.* 14:210
- Trengove, M. C., & Ward, A. C. 2013. SOCS proteins in development and disease. *Am J Clin Exp Immunol.* 2(1): 1–29.



- Vimalraj, S., Miranda, P. J., Ramyakrishna, B., & Selvamurugan, N. 2013. Regulation of breast cancer and bone metastasis by microRNAs. *Dis Markers*. 35(5): 369–87.
- Vincenzi, B., Iuliani, M., Zoccoli, A., Pantano, F., Fioramonti, M., De Lisi, D., *et al.* 2015. Dereglasi of dicer and miR-155 expression in liposarcoma. *Oncotarget*. 6 (12):10586-91.
- Voorhoeve, P. M. 2010. MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity? *Biochim Biophys Acta*. 1805: 72–86.
- Wagner, K.-U., & Schmidt, J. W. 2011. The two faces of Janus kinases and their respective STATs in mammary gland development and cancer (publish online).
- Wang, H., Tan, G., Dong, L., Cheng, L., Li, K., Wang, Z., & Luo, H. 2012. Circulating miR-125b as a marker predicting chemoresistance in breast cancer. *PloS One*. 7(4). 1–8.
- Wang, K., Yuan, Y., Cho, J., McClarty, S., Baxter, D., & Galas, D. J. 2012. Comparing the MicroRNA Spectrum between Serum and Plasma. *PloS One*. 7(7): 1–9.
- Wang, S.E. & Lin, R.J. 2013. MicroRNA and HER2-overexpressing cancer. *Microrna*. 2(2) :137-47.
- Wittmann, J., & Jäck, H.-M. 2010. Serum microRNAs as powerful cancer biomarkers. *Biochim Biophys Acta*. 1806(2): 200–7.
- Yamada, O., Ozaki, K., Akiyama M., & Kawauchi, K. 2012. JAK-STAT and JAK-PI3K-mTORC1 pathway regulate telomerase transcriptionally and posttranslationally in ATL cells. *Mol Cancer Ther*. 11(5): 1112-21.
- Yao, M., Wang, X., Tang, Y., Zhang, W., Cui, B., Liu, Q. *et al.* 2014. Dicer mediating the expression of miR-143 and miR-155 regulates hexokinase II associated cellular response to hypoxia. *AJP-Lung Physiol*. (Publish online)
- Youlden, D. R., Cramb, S. M., Yip, C. H., Baade, P. D., & Asia, S. 2014. Incidence and mortality of female breast cancer in the Asia- Pacific region. *Cancer Biol Med*. 11: 101–115.
- Yu, H., Pardoll, D., & Jove, R. 2009. STATs in cancer inflammation and immunity : a leading role for STAT3. *Nat Rev*. 9: 798–09.

- Zeng, H., Fang, C., Nam, S., Cai, Q., & Long, X. 2014. The clinicopathological significance of microRNA-155 in breast cancer: a meta-analysis. *BioMed Research International*. 2014: 724209.
- Zhang, C.-M., Zhao, J., & Deng, H.-Y. 2013. MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. *J Biomed Sci*. 20: 1–10.
- Zhang, J., Cheng, C., Yuan, X., He, J.-T., Pan, Q.-H., & Sun, F.-Y. 2014. microRNA-155 acts as an oncogene by targeting the tumor protein 53-induced nuclear protein 1 in esophageal squamous cell carcinoma. *Int J Clin Exp Pathol*. 7(2): 602–10.
- Zhao, L., Chen, X., & Cao, Y. 2011. New role of microRNA : carcinogenesis and clinical application in cancer New Role of miRNA in Carcinogenesis. *Acta Biochim Biophys Sin*. 43(11): 831–9.
- Zhao, X., Zhang, W., Liang, H., & Ji, W. 2013. Overexpression of miR -155 Promotes Proliferation and Invasion of Human Laryngeal Squamous Cell Carcinoma via Targeting SOCS1 and STAT3. *PloS One*. 8(2): 1–11.
- Zheng, S.-R., Guo, G.-L., Zhang, W., Huang, G.-L., Hu, X.-Q., Zhu, J., Zhang, X.-H. 2012. Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis. *Oncology Reports*. 27(4): 1149–55.
- Zhu, W., Qin, W., Atasoy, U., & Sauter, E. R. 2009. Circulating microRNAs in breast cancer and healthy subjects. *BMC Res Notes* 2: 1–5.